JXTGE to sell Irvine Scientific to FujiFilm3 Apr 2018
With the acquisition of Irvine Scientific, FujiFilm will have a full product line supporting customers supplying antibody drugs to assisted reproductive technologies and cell therapy.
JXTG Nippon Oil & Energy Corporation has agreed to sell Irvine Scientific Sales Company and IS Japan Co. to FUJIFILM Corporation (FujiFilm).
JXTG Energy acquired Irvine Scientific in 1987 and launched IS Japan in 1989; both companies have continuously expanded to become significant suppliers of cell culture media and products to the biopharmaceutical, cell therapy and medical markets in their respective regions. Although the business has experienced significant growth, life sciences and medical devices are not synergistic for JXTG Energy’s core business going forward.
JXTG Energy determined it would be best for the Irvine Scientific group to continue under ownership which is synergistic to Irvine Scientific products and services.
FujiFilm announced it would acquire the Irvine Scientific group and maximize their synergy in its significant and growing bio-medical businesses. FujiFilm expects increased demand and needs of biopharmaceutical products and regenerative medicine therapy is driving current rapid growth of the cell culture media market and estimates continued strong growth in the coming years.
Irvine Scientific is an innovator of cell culture media, to biopharmaceutical, assisted reproductive technology, and regenerative medicine customers. By applying its high capabilities in R&D and quality systems, coupled with long experience, Irvine Scientific has developed a strong presence serving customer needs. Irvine Scientific’s California, USA and Saitama, Japan cGMP facilities will be transferred and provide capacity to supply high-quality products in a timely manner worldwide.
FujiFilm is advancing growth strategies within healthcare space, investing in biopharmaceutical contract development/manufacturing, and regenerative medicine. Prior to this announcement, FujiFilm acquired the global leader in iPS cell technologies, Cellular Dynamics International (CDI) and has entered into cell culture media space with the acquisition of general reagents manufacturer, Wako Pure Chemical Industries (Wako Pure Chemical). With the acquisition of Irvine Scientific, FujiFilm will have a full product line supporting customers supplying antibody drugs to assisted reproductive technologies and cell therapy, and will also enable FujiFilm to strengthen its overseas business. FujiFilm announced it plans to further accelerate competitive media development and expand cell culture media business by applying chemical synthesis and design technologies acquired through its original business in photographic films and from Japan Tissue Engineering (“J-TEC”), as well as cell growth and manufacturing technologies from CDI and FUJIFILM Diosynth Biotechnologies.
In addition, FujiFilm plans on maximizing synergies outside of cell culture business, combining media technologies and products of Irvine Scientific with FujiFilm Group’s biomedical technologies and products. Specific synergies mentioned include (1) expansion of contract development/manufacturing of biomedicine (2) acceleration of R&D in regenerative medicine (3) expansion of research-purpose chemical reagents business.
The Irvine Scientific Group is excited about this change and anticipates continued acceleration of its cell culture media businesses under new ownership.
BIA Separations expands with new upstream processing facility
20 Sep 2018
Provides single source of expertise for scaled production of complex biologics for gene therapy and vaccines.Read more
Sanofi to refocus two global business units
19 Sep 2018
The new Primary Care and China & Emerging Markets global business units are expected to launch at the beginning of 2019.Read more
Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years
18 Sep 2018
China is harmonizing to ICH standards at feverish pace and will force poor quality manufacturers out of market.Read more
Recipharm connects to European Hub for serialisation compliance
18 Sep 2018
Connection allows the marketing authorisation holders within the Recipharm Group to continue to supply medicines to patients post the EU FMD implementation date.Read more
Bosch to unveil new laboratory device for continuous manufacturing
18 Sep 2018
The Xelum R&D offers pharmaceutical manufacturers an ideal start to continuous OSD production.Read more
Partnership to deliver integrated, off-the-shelf biosimilar manufacturing solutions
17 Sep 2018
Pall and Aetos to advance the market impact of biosimilars and deliver lower-priced, high-quality options to end users.Read more
Cambrex expands manufacturing footprint with acquisition
16 Sep 2018
Completed acquisition adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.Read more
NMPA approves fruquintinib capsules for metastatic colorectal cancer
13 Sep 2018
Fruquintinib - innovative medicine that has not previously been launched in China or internationally - provides a new therapeutic approach for metastatic colorectal cancer patients.Read more
Aptar Pharma to showcase an industry first
12 Sep 2018
PureHale is a new portable drug delivery device designed for upper respiratory care.Read more
Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio
11 Sep 2018
The Sandoz US portfolios to be sold to Aurobindo include approximately 300 products, as well as additional development projects.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation